[
  {
    "ts": null,
    "headline": "AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus",
    "summary": "AbbVie has agreed to lower prices on certain Medicaid drugs in exchange for exemptions from pharmaceutical import tariffs and future price controls. The company plans significant new investment in U.S. research and development and is expanding its Arizona manufacturing facility. The moves signal a shift toward greater domestic production and closer negotiation with regulators on long term oversight. AbbVie, trading on the NYSE under ticker NYSE:ABBV, is drawing attention as it reshapes its...",
    "url": "https://finnhub.io/api/news?id=c1cdb9eadc9d8e616bfa3a1be50b129aa4e1dd3e26fb67d900ba7eb9b49e6e3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770754175,
      "headline": "AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus",
      "id": 139036296,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie has agreed to lower prices on certain Medicaid drugs in exchange for exemptions from pharmaceutical import tariffs and future price controls. The company plans significant new investment in U.S. research and development and is expanding its Arizona manufacturing facility. The moves signal a shift toward greater domestic production and closer negotiation with regulators on long term oversight. AbbVie, trading on the NYSE under ticker NYSE:ABBV, is drawing attention as it reshapes its...",
      "url": "https://finnhub.io/api/news?id=c1cdb9eadc9d8e616bfa3a1be50b129aa4e1dd3e26fb67d900ba7eb9b49e6e3f"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on AstraZeneca: “We Want Every Drug Stock”",
    "summary": "AstraZeneca PLC (NASDAQ:AZN) is one of the stocks in focus on Jim Cramer’s game plan. Cramer mentioned the company during the episode and said: On Tuesday, we’re back in heavy earnings rotation. We’ve got DuPont, Coca-Cola, CVS Health, AstraZeneca, Datadog, and S&P Global report… Oh, also, AstraZeneca, we want every drug stock. They’re all working. […]",
    "url": "https://finnhub.io/api/news?id=577b05fc89d72e6a259291c92541e3b4a54496678748c5e5ce6379e7272373fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770739175,
      "headline": "Jim Cramer on AstraZeneca: “We Want Every Drug Stock”",
      "id": 139033435,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AstraZeneca PLC (NASDAQ:AZN) is one of the stocks in focus on Jim Cramer’s game plan. Cramer mentioned the company during the episode and said: On Tuesday, we’re back in heavy earnings rotation. We’ve got DuPont, Coca-Cola, CVS Health, AstraZeneca, Datadog, and S&P Global report… Oh, also, AstraZeneca, we want every drug stock. They’re all working. […]",
      "url": "https://finnhub.io/api/news?id=577b05fc89d72e6a259291c92541e3b4a54496678748c5e5ce6379e7272373fa"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals",
    "summary": "AbbVie’s latest agreement with the Trump administration underscores a major shift in US drug pricing policy, one in which domestic manufacturing is no longer a peripheral concern but it is built into the deal itself.",
    "url": "https://finnhub.io/api/news?id=91096ba3e344b46f39b8fff5d40adc6cf23343a3f3fbcbd373cd0780cde861d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770737383,
      "headline": "AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals",
      "id": 139031867,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie’s latest agreement with the Trump administration underscores a major shift in US drug pricing policy, one in which domestic manufacturing is no longer a peripheral concern but it is built into the deal itself.",
      "url": "https://finnhub.io/api/news?id=91096ba3e344b46f39b8fff5d40adc6cf23343a3f3fbcbd373cd0780cde861d7"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=0762c98dbc0bebfd1b602370eb41dc7fcba24bdacb411eb20a97d237b7fa1733",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770732006,
      "headline": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know",
      "id": 139031868,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=0762c98dbc0bebfd1b602370eb41dc7fcba24bdacb411eb20a97d237b7fa1733"
    }
  },
  {
    "ts": null,
    "headline": "Here's What Will Drive AbbVie's Top-line Growth in 2026",
    "summary": "ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.",
    "url": "https://finnhub.io/api/news?id=7019bfc40bd1a78a2625543202f89e570dc23fc764419fff1cabc9f7bb95b378",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770730320,
      "headline": "Here's What Will Drive AbbVie's Top-line Growth in 2026",
      "id": 139031857,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.",
      "url": "https://finnhub.io/api/news?id=7019bfc40bd1a78a2625543202f89e570dc23fc764419fff1cabc9f7bb95b378"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Kings: No Ideal Buys In February's 57",
    "summary": "Dividend Kings: No Ideal Buys In February's 57",
    "url": "https://finnhub.io/api/news?id=748ad605c74258420cb433a0339c2948a94eaca5ec2b74773a4551ba8207fcf7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770716712,
      "headline": "Dividend Kings: No Ideal Buys In February's 57",
      "id": 139031435,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=748ad605c74258420cb433a0339c2948a94eaca5ec2b74773a4551ba8207fcf7"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
    "summary": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
    "url": "https://finnhub.io/api/news?id=e81d72ae20afbebf3fb8841caae7adbb69cb25fe0e1e1f62e222e0a30a1acee9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770702333,
      "headline": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
      "id": 139028076,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e81d72ae20afbebf3fb8841caae7adbb69cb25fe0e1e1f62e222e0a30a1acee9"
    }
  }
]